The 36-month beta value for ATXS is also noteworthy at 0.38. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATXS is 45.57M, and at present, short sellers hold a 6.62% of that float. The average trading volume of ATXS on June 19, 2025 was 483.57K shares.
ATXS) stock’s latest price update
The stock of Astria Therapeutics Inc (NASDAQ: ATXS) has increased by 3.33 when compared to last closing price of 5.70. Despite this, the company has experienced a 1.73% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-18 that BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “Advances in Dermatology: AD and CSU” on Wednesday, June 25 at 10:.
ATXS’s Market Performance
Astria Therapeutics Inc (ATXS) has experienced a 1.73% rise in stock performance for the past week, with a 38.26% rise in the past month, and a -6.66% drop in the past quarter. The volatility ratio for the week is 3.54%, and the volatility levels for the past 30 days are at 5.66% for ATXS. The simple moving average for the last 20 days is 14.98% for ATXS stock, with a simple moving average of -26.44% for the last 200 days.
Analysts’ Opinion of ATXS
Many brokerage firms have already submitted their reports for ATXS stocks, with Cantor Fitzgerald repeating the rating for ATXS by listing it as a “Overweight.” The predicted price for ATXS in the upcoming period, according to Cantor Fitzgerald is $47 based on the research report published on April 29, 2025 of the current year 2025.
JMP Securities, on the other hand, stated in their research note that they expect to see ATXS reach a price target of $26. The rating they have provided for ATXS stocks is “Mkt Outperform” according to the report published on January 31st, 2025.
TD Cowen gave a rating of “Buy” to ATXS, setting the target price at $35 in the report published on July 29th of the previous year.
ATXS Trading at 24.76% from the 50-Day Moving Average
After a stumble in the market that brought ATXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.41% of loss for the given period.
Stock Fundamentals for ATXS
The total capital return value is set at -0.42. Equity return is now at value -32.89, with -31.35 for asset returns.
Based on Astria Therapeutics Inc (ATXS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -18.99.
Currently, EBITDA for the company is -94.26 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.39.
Conclusion
In summary, Astria Therapeutics Inc (ATXS) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
